A Study to Evaluate MORF-057 in Adults With Moderately to Severely Active UC

Inclusion Criteria

• •Has signs/symptoms of moderate to severe UC for at least 3 months prior to Screening
• •Has evidence of UC extending at least 15 cm from the anal verge
• •Demonstrated an inadequate response, loss of response, or intolerance to at least one of the following treatments: Oral aminosalicylates (e.g., mesalamine, sulfasalazine, olsalazine, or balsalazide), corticosteroids, immunosuppressants (e.g., azathioprine, 6-mercaptopurine, or methotrexate), advanced therapies for UC (e.g., biologic agents, Janus kinase \[JAK\] antagonists, or sphingosine-1-phosphate \[S1P\] receptor agonists)
• •Subject has no prior exposure to approved or investigational anti-integrin therapies
• •Agrees to abide by the study guidelines and requirements
• •Capable of giving signed informed consent